- Condition: Vestibulodynia
Intervention: Behavioral: Cognitive-behavioral couple therapy (CBCT)
Sponsors: Université de Montréal; Université de Montréal
Not yet recruiting - verified May 2012 - Conditions: Tetraplegia; Plegia; Paresis; Cervical Spinal Cord Injury
Intervention: Procedure: Nerve reconstruction
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified April 2012 - Condition: HIV Infection
Intervention: Other: monetary reinforcer
Sponsors: University of British Columbia; University of British Columbia; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: Multiple Sclerosis; Fatigue
Interventions: Drug: Testosterone undecanoate; Drug: placebo
Sponsors: Health Sciences Centre, Winnipeg, Manitoba; Health Sciences Centre, Winnipeg, Manitoba; University of Manitoba; Consortium of Multiple Sclerosis Centers; Manitoba Medical Service Foundation
Not yet recruiting - verified January 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Conditions: Genital Warts; HPV
Interventions: Drug: Oral Zinc; Drug: Placebo
Sponsors: University of British Columbia; University of British Columbia; British Columbia Centre for Disease Control
Not yet recruiting - verified November 2011 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Vestibulodynia
Interventions: Procedure: Multimodal physiotherapy; Drug: lidocaine
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Canadian Institutes of Health Research (CIHR); Fonds de la Recherche en Santé du Québec
Recruiting - verified October 2011 - Condition: Movement Disorders
Intervention: Other: Wheelchair skills training program
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified September 2011 - Condition: Breast Neoplasms
Interventions: Other: Volume of Exercise; Moderate or High Volume; Other: Aerobic Exercise; Other: Aerobic Exercise
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified September 2011 - Conditions: Ejaculatory Dysfunction; Hypogonadism
Interventions: Drug: Testosterone Solution 2%; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012 - Condition: Narcolepsy
Intervention: Other: No intervention
Sponsors: Hopital du Sacre-Coeur de Montreal; Hopital du Sacre-Coeur de Montreal; GlaxoSmithKline
Recruiting - verified July 2011 - Condition: Inguinal Hernia
Intervention: Procedure: Isolation of the spermatic cord from mesh
Sponsors: Chatham Kent Health Alliance; Chatham Kent Health Alliance
Recruiting - verified July 2011 - Condition: Treatment Outcome
Interventions: Drug: Lu AA21004; Drug: Escitalopram
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Depression With Prominent Agitation
Interventions: Drug: Quetiapine XR; Drug: Escitalopram
Sponsors: Physicians Research And Education Network; Physicians Research And Education Network
Recruiting - verified May 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Fragile X Syndrome
Interventions: Drug: AFQ056; Drug: AFQ056; Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Early Inflammatory Arthritis
Interventions: Behavioral: One-on-one peer support; Behavioral: Standard of care
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Rheumatology Association; Mount Sinai Hospital, Toronto, Canada; The Arthritis Society, Canada; St. Michael's Hospital, Toronto; University of Toronto
Recruiting - verified December 2011 - Condition: HIV Infection
Interventions: Drug: atazanavir; Drug: atazanavir/ritonavir
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified September 2011 - Condition: Fragile X Syndrome
Intervention: Drug: AFQ056
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Fragile X Syndrome
Interventions: Drug: AFQ056; Drug: AFQ056; Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: HIV Infection
Interventions: Biological: AGS-004; Biological: Placebo
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified November 2011 - Conditions: Postmenopause; Overweight
Interventions: Behavioral: Placebo + exercise; Dietary Supplement: Phytoestrogens without exercise; Other: Phytoestrogens + exercise; Other: Placebo without exercise
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Canadian Institutes of Health Research (CIHR); Centre de recherche sur le vieillissement du CSSS-IUGS
Recruiting - verified June 2010 - Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: LY2216684
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Hypercholesterolemia; HIV Infections
Interventions: Drug: Ezetimibe; Drug: Rosuvastatin (standard care)
Sponsors: University of British Columbia; University of British Columbia; Merck Frosst-Schering Pharma, G.P.
Recruiting - verified November 2011 - Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Conditions: Prostate Cancer; Erectile Dysfunction; Urinary Toxicity
Interventions: Drug: LHRH agonist and Bicalutamide; Drug: Bicalutamide, Dutasteride and Tamoxifen
Sponsors: Centre hospitalier universitaire de Québec; Centre hospitalier universitaire de Québec; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: HIV Infections
Intervention:
Sponsors: Radboud University; Radboud University; PENTA Foundation; Merck; Bristol-Myers Squibb; CIHR Canadian HIV Trials Network
Recruiting - verified October 2011 - Condition: HIV Infection
Interventions: Dietary Supplement: Micronutrients and antioxidants; Dietary Supplement: Multivitamins and minerals
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian HIV Trials Network; Ontario HIV Treatment Network
Recruiting - verified July 2011 - Condition: Bacterial Vaginosis
Interventions: Drug: Gelatin; Drug: Boric acid; Drug: Metronidazole
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Cervical Cancer
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified July 2011 - Condition: Autonomic Dysreflexia
Intervention: Drug: Prazosin HCL
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified February 2012 - Condition: Prostate Cancer
Intervention: Drug: luteinizing hormone-releasing hormone (LHRH) short acting or long acting
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012
 |
Join Clinical Trials for Sexual Diseases in Canada |
